Скачать с ютуб Early results from INCB123667 in cyclin E1 overexpressing/CCNE1-amplified cancers в хорошем качестве

Early results from INCB123667 in cyclin E1 overexpressing/CCNE1-amplified cancers

Matteo Simonelli, MD, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, Italy, discusses the Phase I trial (NCT05238922) of INCB123667, a selective CDK2 inhibitor, in patients with advanced solid tumors, particularly those with cyclin E1 overexpression or CCNE1 amplification. INCB123667 was generally well tolerated, especially in patients with ovarian cancer, with common treatment-related adverse events including thrombocytopenia, nausea, and anemia. Promising antitumor activity was observed, and ongoing trials will further evaluate the drug in specific tumor cohorts. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.